|
|
 |
Registry of Lobbyists - Fakher Aissa
To find further information on a company or organization check the Registry of Joint Stock Companies
|
|
| Registration Number | Status | | | 987 | Terminated | | | Initial registration date | Last date of any changes | | 11-January-2012 | 23-January-2013 |
|
Lobbyist's Last Name
Aissa |
Lobbyist's First Name
Fakher |
Middle Initial
|
|
Business Address of Lobbyist
1000, Rue de la Gauchetiere West - Suite 500 |
City
Montreal |
Province/State
PQ |
Country
CA |
Postal/Zip Code
H3B 4W5 |
Telephone
(514) 940-9430 |
Fax
(514) 844-5495 |
| |
Business or Firm Name for Lobbyist (if applicable)
Lundbeck Canada Inc. |
Registry of Joint Stock Companies Number
N/A |
Business Address of Lobbyist's Business or Firm
1000, Rue de la Gauchetiere West - Suite 500 |
City
Montreal |
Province/State
PQ |
Country
CA |
Postal/Zip Code
H3B 4W5 |
Telephone
(514) 940-9430 |
Fax
(514) 844-5495 |
|
| Beneficiary Name |
Beneficiary Type |
|
| H. Lundbeck A/S |
Parent Company |
View
|
|
|
|
|
Description of Employer's Business:
Lundbeck Canada Inc. develops, manufactures and/or sells innovative biopharmaceutical medicines for the treatment of disorders originating in the central nervous system (CNS) and for the treatment of cancer. Lundbeck Canada is a wholly-owned subsidiary of H. Lundbeck A/S, a publicly-traded company in Denmark with shareholders. |
| |
|
|
|
| Description |
|
| Focus on ensuring changes to biopharmaceutical legislation & related policies and programs reflect innovative research & development policies, and recognize the value of Lundbeck’s contribution to the Nova Scotia health and life sciences sector economies. Focus on ensuring biopharmaceutical and related legislation, regulations, policies and programs support appropriate reimbursement of biopharmaceuticals by payers and improved patient access to new treatments, with emphasis on advocating for products, services and disease management strategies effective for the treatment and management of cancer. |
View
|
|
|
|
|
|
No funding from any government or agency
|
|
No private funding related to lobbying activities
|
|
|
|
|
